A randomized controlled trial on the use of magnesium sulfate and melatonin in neonatal hypoxic ischemic encephalopathy.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The aim of this trial on infants with HIE who are receiving melatonin therapy, is to assess the added effect of magnesium sulfate (MgSO4) on the expression of S100-B, a marker of brain injury.

Why It Was Studied

Birth asphyxia is a leading case of neonatal morbidity and mortality especially in developing countries.

Hypoxic-ischemic encephalopathy (HIE) attributed to asphyxia can be ameliorated with several remedies, although full recovery is currently not feasible.

Who Took Part

PubMed tags the participants as both men and women.

How the Study Was Run

The design is described as randomized.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

This study is a randomized controlled trial on neonates with moderate HIE (Sarnat grade II).

Infants were randomized into 2 groups; group1 who received MgSO4 and melatonin; and group 2 who received melatonin only.

Serum concentrations of S100-B were measured at baseline, and at days 2 and 6 of therapy.

What Was Measured

The subject headings attached to it are Asphyxia Neonatorum, Biomarkers, Electroencephalography, Hypoxia-Ischemia, Brain, Magnesium Sulfate, Melatonin and Neuroprotective Agents.

Author keywords: neonate.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Journal of neonatal-perinatal medicine), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.